Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver
On November 24, Truist’s Gregory Renza initiated coverage of Gilead Sciences, Inc.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,462,744 | $606,364,584 | -4% | 0.8% |
| 2. | Citadel Investment Group Ken Griffin | 5,207,666 | $578,050,926 | -5% | 0.09% |
| 3. | Holocene Advisors Brandon Haley | 2,617,172 | $290,506,092 | -39% | 0.66% |
| 4. | AQR Capital Management Cliff Asness | 2,379,546 | $264,129,514 | -4% | 0.17% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,901,480 | $211,064,280 | -3% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $125.08 | 5,000 | $625,400.00 | 8,920 | 2025-11-28 | Filing | |
| $127.10 | 2,805 | $356,515.50 | 1,339 | 2025-11-28 | Filing | |
| $127.11 | 2,806 | $356,670.66 | 1,339 | 2025-11-26 | Filing | |
| $126.84 | 6,788 | $861,015.71 | 571,203 | 2025-11-28 | Filing | |
| $125.91 | 3,212 | $404,428.06 | 577,991 | 2025-11-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 118,983,644 | $13,207,184,484 | 0.2% | |
| 2. | 116,281,391 | $12,907,234,450 | 0.23% | |
| 3. | 60,316,279 | $6,695,106,838 | 0.35% | |
| 4. | 59,089,305 | $6,558,912,855 | 0.23% | |
| 5. | 45,179,931 | $5,015,468,946 | 0.69% |
News See All
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline
Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc.
15 Best Boring Dividend Stocks to Buy
Investing in high-quality dividend growth stocks may not seem very exciting.
12 Best Slow Growth Stocks to Invest In
On the night of November 27, during a week cut by Thanksgiving, stock futures saw minimal movement, with the Nasdaq Composite poised to end a seven-month winning run.
Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD
On November 12, Scotiabank analyst Louise Chen began coverage on ten large-cap biopharma companies and shared an “out-of-consensus” positive view on the sector, according...
15 Best Passive Income Stocks to Buy Right Now
The idea of generating passive income has been gaining a lot of attention recently.
Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc.
13 Best Blue Chip Stocks to Buy Now
Blue-chip stocks are well-positioned to emerge as the ultimate winners amid the Trump tariffs and a shift in monetary policy.
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Third Quarter 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
RBC Warns Gilead (GILD) Faces Risk from Trump's Price Cut Target
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 1, RBC analysts stated that Gilead Sciences, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
